Story
Aquestive Therapeutics Shares Gain After Positive Anaphylaxis Drug Study Results

Shares of Aquestive Therapeutics (NASDAQ: AQST) surged in pre-market trading after the company reported positive topline results from two pivotal studies for its lead drug candidate, Anaphylm. The drug is a non-invasive, sublingual film designed to treat severe allergic reactions, including anaphylaxis.
Addressing FDA Concerns
The company announced favorable data from a human factors validation study and a self-administration pharmacokinetic study. According to Aquestive, these results directly address concerns raised by the U.S. Food and Drug Administration (FDA) in a Complete Response Letter (CRL) issued in January 2026.
The positive data is a significant milestone, as it removes a key regulatory overhang for the company. Aquestive confirmed that its New Drug Application (NDA) resubmission for Anaphylm remains on track for the third quarter of 2026.
AdMarket Impact and Outlook
Following the announcement, Aquestive's stock jumped 9.4% in pre-open trading. The move was driven by the reduced regulatory risk, as investors had been monitoring whether the company could complete the required studies on schedule.
If approved, Anaphylm has the potential to be the first non-invasive epinephrine product for anaphylaxis available in the market, a position that could hold significant commercial value. The muted trading in the broader U.S. equity markets highlighted that the stock's surge was a direct reaction to the company-specific news.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.